Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Prudential Financial Inc (PRU) vs Summit Therapeutics Inc (SMMT) Price & Performance

Prudential Financial IncTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Prudential Financial Inc vs Summit Therapeutics Inc — how do they compare? Prudential Financial Inc trades at $118.18 (market cap $40.97B), while Summit Therapeutics Inc trades at $14.78 (market cap $11.34B). The key difference: Prudential Financial Inc is far larger — about 3.6× Summit Therapeutics Inc's market cap, and Prudential Financial Inc pays a 4.75% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.

PRUSMMT
Market Cap
$40.97B$11.34B
Sector
FinancialsHealth
52-Week High
$119.07$29.32
52-Week Low
$92.00$13.05
Enterprise Value
$68.03B$10.76B
Dividend Yield
4.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Prudential Financial Inc

No Aura AI signal available yet.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.

The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Prudential Financial Inc

Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.

Read more on PRU

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT